Panther Life Sciences reports favorable first skin tolerability results for SmartPatch

Panther Life Sciences said its SmartPatch microarray patch was well tolerated in a first clinical skin study of repeated use on crow’s feet over four weeks. The company plans a 40-subject efficacy trial later this year, with results expected in early 2027.

Why it matters: - Panther Life Sciences has an early clinical signal for SmartPatch, its dissolvable microarray patch designed to deliver active ingredients through the skin. - The tolerability data help support the company’s move from safety testing into a dedicated efficacy study. - Skin smoothing is the first planned use of SmartPatch, which Panther is also developing for broader health, wellness and therapeutic applications.

What happened: - Panther Life Sciences announced positive results from a clinical skin tolerability study of SmartPatch on October 14, 2026. - The study tested repeated applications on the lateral canthal lines, or crow’s feet, in healthy adults. - The independent study enrolled 16 healthy adults, and 13 completed eight applications over four weeks plus a one-week post-treatment follow-up. - The study protocol was reviewed and approved by the Clarus Institutional Review Board.

The details: - SmartPatch showed favorable skin tolerability after repeated applications over four weeks. - Irritation profiles were comparable to adhesive-only control patches. - No adverse events or unexpected skin reactions were reported. - Skin-barrier integrity stayed intact under the study conditions. - There were no statistically significant differences between SmartPatch and control sites in transepidermal water loss, or TEWL. - Board-certified dermatologists assessed tolerability using a standardized irritation scale. - Exploratory imaging using VISIA®-CR found early signals of improvement. - The study was not designed to measure efficacy. - Panther said a dedicated 40-subject efficacy trial is scheduled for later this year.

Between the lines: - The results give Panther an initial proof-of-concept readout, but they are still limited to a small study in healthy adults. - The absence of efficacy testing means the findings support safety and skin response, not clinical benefit. - The use of repeated occlusion on the periorbital area adds relevance because that is the intended area of use. - Saeid Amini Nik, MD, PhD, principal investigator at SGS North America, said the lack of clinically meaningful irritation or adverse events, along with the skin-barrier findings, supports continued clinical evaluation of SmartPatch. - CEO Marcus “Mounir” Hanana said the company’s goal is to establish safety and efficacy first in skin health before expanding the platform.

What's next: - Panther expects the efficacy study to finish in early 2027. - After that, the company plans to prepare a final clinical study report. - Panther also plans to submit the findings for publication in peer-reviewed scientific journals. - The company says SmartPatch is designed for future uses across health, wellness and therapeutics.

The bottom line: - Panther has cleared an early tolerability hurdle for SmartPatch, setting up the next test: whether the patch can deliver measurable efficacy in a larger study.